+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Brain Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Brain Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011103
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Cancer Diagnostics Market is projected to reach USD 2.19 Billion in 2026. It is expected to continue growing at a CAGR of 10.62%, reaching USD 4.03 Billion by 2032.

Brain cancer diagnostics is moving from a primarily anatomy-based discipline to an integrated diagnostic model combining MRI, histopathology, immunohistochemistry, molecular pathology, next-generation sequencing, and increasingly liquid biopsy research. The World Health Organization’s CNS tumor classification emphasizes molecular features such as IDH mutation status, 1p/19q codeletion, H3 K27 alteration, TERT promoter mutation, ATRX loss, and MGMT promoter methylation, making precision diagnostics central to treatment selection, prognosis, and clinical trial eligibility.

The clinical need is substantial. GLOBOCAN 2022 estimates about 322,000 new brain and central nervous system cancer cases and approximately 248,000 deaths worldwide, underscoring the urgency for earlier detection, accurate tumor grading, and faster molecular turnaround. For hospitals, diagnostic laboratories, imaging centers, and technology vendors, the brain cancer diagnostics landscape is increasingly defined by workflow integration, evidence-based biomarker testing, quality-assured imaging, and multidisciplinary tumor-board adoption.

Transformative Shifts in the Diagnostic Landscape

The brain cancer diagnostics landscape is being reshaped by three connected shifts: molecular classification, digital workflow adoption, and demand for minimally invasive monitoring. Conventional MRI remains foundational for detection, surgical planning, and treatment response assessment, but advanced MRI techniques, amino-acid PET in selected settings, perfusion imaging, spectroscopy, and integrated radiology-pathology review are improving diagnostic confidence.

Pathology is also changing. The WHO framework has made molecular testing indispensable rather than optional, particularly for adult diffuse gliomas and pediatric high-grade gliomas. This shift is increasing demand for validated NGS panels, methylation profiling in complex cases, robust tissue stewardship, and standardized reporting aligned with clinical guidelines. At the same time, cerebrospinal fluid and plasma-based liquid biopsy approaches are gaining research momentum for tumors where tissue access is limited, although clinical deployment still depends on analytical validation, regulatory acceptance, and demonstrated patient benefit.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across imaging triage, segmentation, radiomics, pathology image analysis, molecular prediction, and clinical decision support. AI tools can support reproducible tumor volume measurement, identify subtle imaging patterns, assist treatment response evaluation, and reduce repetitive manual workload; however, clinical value depends on external validation, explainability, bias monitoring, and integration with radiologist and pathologist workflows.

In brain cancer diagnostics, AI is most credible when positioned as an assistive layer rather than an autonomous substitute for expert interpretation. Data-backed implementation requires diverse training datasets, prospective performance monitoring, cybersecurity controls, and governance under medical device regulations. Organizations that combine AI with standardized MRI protocols, structured pathology data, and genomic results are better positioned to improve turnaround time, multidisciplinary coordination, biomarker interpretation, and eligibility screening for targeted therapies and clinical trials.

Key Regional Insights

North America remains a leading region for brain cancer diagnostics because of high MRI availability, broad adoption of molecular pathology, strong academic cancer centers, and established reimbursement pathways for clinically justified genomic testing. The United States and Canada benefit from active clinical trial networks, neuro-oncology subspecialization, and guideline-driven oncology care, although rural access, insurance complexity, and out-of-pocket costs continue to affect diagnostic equity.

Europe is shaped by centralized cancer networks, national health technology assessment, and the European Union’s regulatory emphasis on in vitro diagnostic performance, medical device oversight, and data protection. Asia-Pacific combines world-class diagnostic capacity in Japan, South Korea, Australia, China’s major urban centers, and Singapore with uneven access across lower-resource settings; rising neuro-oncology investment, expanding sequencing infrastructure, and digital imaging adoption are key growth drivers. Latin America is seeing increasing demand for MRI, pathology modernization, and referral-based molecular testing, led by larger urban health systems in Brazil and Mexico, while affordability and public-sector capacity remain persistent barriers. The Middle East is advancing through tertiary care investment, national cancer strategies, and international care partnerships, particularly in GCC health systems. Africa faces the greatest infrastructure constraints, including limited MRI availability, shortages of neuropathology specialists, and delayed diagnosis, yet regional referral centers and telepathology initiatives are gradually improving access to brain cancer diagnostics.

Key Group Insights

Across the G7, brain cancer diagnostics adoption is supported by mature imaging infrastructure, specialist neuro-oncology centers, recognized clinical guidelines, and reimbursement systems that increasingly treat molecular markers as clinically necessary. NATO countries overlap with many high-income health systems, supporting cross-border research collaboration, cybersecurity requirements for health data, and harmonized procurement standards for advanced diagnostic platforms.

The European Union is influential through regulatory frameworks for medical devices, in vitro diagnostics, and health data governance, creating higher evidence thresholds for diagnostic innovators while encouraging standardized quality systems. BRICS countries are strategically important because China, India, and Brazil combine large patient populations with expanding genomics and hospital investments, while Russia and South Africa contribute regional referral capacity and specialist expertise. ASEAN markets vary widely, with Singapore and Malaysia advancing precision oncology and digital pathology adoption, while other member states continue prioritizing MRI access, neuropathology training, and affordable molecular testing. GCC countries are investing in tertiary care, medical tourism, oncology centers, and national cancer strategies that favor advanced imaging, reference laboratory partnerships, and molecular testing adoption.

Key Country Insights

The United States anchors innovation through comprehensive cancer centers, regulated diagnostics, broad clinical trial activity, and high use of MRI and molecular profiling. Canada emphasizes publicly funded care, regional cancer programs, and quality-assured pathology networks, while Mexico and Brazil are expanding oncology infrastructure but face access disparities between private and public systems. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine guideline-based care with national reimbursement review, established neuro-oncology services, and increasing use of molecular classification, while Russia maintains strong urban specialist centers amid regional variation in access.

China is scaling hospital-based sequencing, AI imaging research, and tertiary neuro-oncology services, particularly in major metropolitan hospitals; India is growing rapidly in private diagnostics and oncology networks while addressing affordability, specialist distribution, and geographic access. Japan and South Korea offer advanced imaging, pathology quality, and digital health capacity, supported by aging populations, clinical research activity, and strong medical technology ecosystems. Australia benefits from integrated cancer registries, clinical trial participation, high-standard pathology networks, and advanced imaging access, making it an important precision neuro-oncology market with strong alignment to evidence-based diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, workflow-ready diagnostic solutions rather than standalone technologies. The strongest opportunities are in integrated platforms that connect MRI, pathology, genomic testing, methylation analysis, structured reporting, and tumor-board decision support while reducing turnaround time and preserving tissue for essential assays.

Vendors and providers should invest in evidence generation, including multi-center validation, analytical performance studies, health economic analysis, and real-world performance monitoring. Partnerships with academic hospitals, reference laboratories, clinical trial networks, and patient advocacy groups can accelerate adoption. Leaders should also design for interoperability, cybersecurity, regulatory compliance, and equitable access, because payers and health systems increasingly expect measurable clinical utility, reproducibility, and operational value, not only technical performance.

Research Methodology

This executive summary is developed from publicly available and verifiable sources, including WHO CNS tumor classification principles, IARC/GLOBOCAN cancer burden estimates, national cancer institute materials, peer-reviewed neuro-oncology literature, regulatory guidance, and recognized clinical practice guidelines. The analysis emphasizes diagnostic technologies with established or emerging clinical relevance, including MRI, histopathology, immunohistochemistry, molecular profiling, NGS, methylation analysis, digital pathology, AI-enabled imaging support, and liquid biopsy research.

The methodology uses triangulation across epidemiology, clinical guidelines, technology adoption patterns, regulatory considerations, regional healthcare infrastructure, and documented clinical workflow requirements. Insights are presented qualitatively where reliable comparable market figures are not publicly standardized, avoiding unsupported numerical claims. The focus is on evidence-backed strategic implications for stakeholders operating in brain cancer diagnostics.

Conclusion

Brain cancer diagnostics is entering a precision-driven phase where accurate classification, molecular confirmation, and rapid multidisciplinary interpretation directly influence therapy selection, trial eligibility, and patient counseling. The burden of CNS cancers and the complexity of glioma biology make diagnostic quality a strategic priority for health systems, laboratories, imaging providers, and technology developers.

Sustainable progress will depend on validated biomarkers, scalable molecular testing, AI-enabled workflow efficiency, regulatory-grade evidence, and equitable access to advanced imaging and pathology. Organizations that combine scientific rigor with practical implementation will be best positioned to lead in the evolving brain cancer diagnostics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Molecularly Integrated Classification Converts Testing into a Standard Diagnostic Requirement
4.3.1.2. Advanced Imaging Demand Sustains Premium Instrument and Software Investment
4.3.1.3. AI Productivity Gains Address Specialist Shortages and Workflow Bottlenecks
4.3.1.4. Cancer Infrastructure Expansion Broadens Access to High-Acuity Neuro-Oncology Diagnostics
4.3.2. Key Restraints
4.3.2.1. High Capital Intensity and Budget Cyclicality Slow System-Level Adoption
4.3.2.2. Reimbursement Variability Limits Uptake of Advanced Molecular and AI Workflows
4.3.3. Key Opportunities
4.3.3.1. CSF Liquid Biopsy Can Create a New Monitoring and Recurrence Revenue Layer
4.3.3.2. Rapid Intraoperative Molecular Classification Opens a Premium Surgical Workflow Segment
4.3.3.3. Integrated Neuro-Oncology Tumor Board Platforms Can Capture Multimodal Decision Intelligence
4.3.4. Key Challenges
4.3.4.1. Interoperability Gaps Limit the Full Value of Multimodal Diagnosis
4.3.4.2. Geopolitical Supply Risk Raises Cost, Lead Time, and Service Exposure
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Brain Cancer Diagnostics Market, by Offering
7.1. Introduction
7.2. Instruments
7.2.1. Imaging Instruments
7.2.1.1. Magnetic Resonance Imaging (MRI) Systems
7.2.1.1.1. Closed
7.2.1.1.2. Open
7.2.1.2. Computed Tomography (CT) Scan Systems
7.2.1.3. Positron Emission Tomography (PET) Systems
7.2.1.4. Ultrasound Systems
7.2.2. Molecular & Pathology Instruments
7.2.2.1. Sequencers
7.2.2.2. Polymerase Chain Reaction (PCR) Systems
7.2.2.3. Microarray Systems
7.2.2.4. Fluorescence In Situ Hybridization (FISH) Platforms
7.2.2.5. Next-Generation Sequencing (NGS) Systems
7.2.3. Tissue Acquisition Instruments
7.2.3.1. Biopsy Needles
7.2.3.2. Stereotactic Frames
7.2.3.3. Neuronavigation Systems
7.2.3.4. Endoscopic Sampling Devices
7.3. Consumables & Reagents
7.3.1. Imaging Consumables
7.3.1.1. Contrast Agents
7.3.1.2. Radiotracers
7.3.1.3. Calibration Phantoms
7.3.2. Molecular Reagents
7.3.2.1. Sample Preparation Kits
7.3.2.2. Extraction Kits
7.3.2.3. Library Preparation Kits
7.3.2.4. Sequencing Reagents
7.3.3. Pathology Consumables
7.3.3.1. Antibodies
7.3.3.2. Probes
7.3.3.3. Stains
7.3.3.4. Slides & Cassettes
7.3.3.5. Fixatives
7.4. Services
7.4.1. Imaging Services
7.4.1.1. Radiology Reading Services
7.4.1.2. Advanced Imaging Quantification Services
7.4.2. Pathology
7.5. Software & Analytics
7.5.1. Imaging Analytics
7.5.2. Genomic Analytics
7.5.3. Pathology Informatics
8. Brain Cancer Diagnostics Market, by Tumor Type
8.1. Introduction
8.2. Primary Brain Tumors
8.2.1. Benign
8.2.1.1. Chordomas
8.2.1.2. Glomus Jugulare
8.2.1.3. Meningiomas
8.2.1.4. Pituitary Adenomas
8.2.2. Malignant
8.2.2.1. Medulloblastomas
8.2.2.2. Astrocytomas
8.2.2.3. Glioblastomas multiforme
8.3. Secondary Brain Tumors
9. Brain Cancer Diagnostics Market, by Sample Type
9.1. Introduction
9.2. Tissue Samples
9.3. Biofluid Samples
9.3.1. Blood Samples
9.3.2. Cerebrospinal Fluid Samples
10. Brain Cancer Diagnostics Market, by Tumor Grade Type
10.1. Introduction
10.2. Grade IV
10.3. Grade III
10.4. Grade II
10.5. Grade I
11. Brain Cancer Diagnostics Market, by Clinical Application
11.1. Introduction
11.2. Diagnosis & Characterization
11.2.1. Initial Detection
11.2.2. Differential Diagnosis
11.2.3. Pre-Treatment Assessment
11.2.3.1. Preoperative Tumor Mapping
11.2.3.2. Surgical Planning
11.2.3.3. Radiation Planning
11.3. Molecular & Pathologic Workup
11.3.1. Classification & Subtyping
11.3.2. Grading & Prognosis
11.3.3. Treatment Selection
11.4. Monitoring & Recurrence Assessment
11.4.1. Response Monitoring
11.4.2. Surveillance & Follow-Up
11.4.3. Disease Tracking
12. Brain Cancer Diagnostics Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Diagnistics Laboratories
12.5. Academic & Research Institutes
13. Brain Cancer Diagnostics Market, by Region
13.1. North America
13.2. Europe
13.3. Asia-Pacific
13.4. Latin America
13.5. Middle East
13.6. Africa
14. Brain Cancer Diagnostics Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Brain Cancer Diagnostics Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Canada
15.5. Japan
15.6. United Kingdom
15.7. France
15.8. Brazil
15.9. South Korea
15.10. India
15.11. Mexico
15.12. Italy
15.13. Australia
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Siemens Healthineers AG
17.2. GE HealthCare Technologies Inc.
17.3. Koninklijke Philips N.V.
17.4. Canon Medical Systems Corporation
17.5. Thermo Fisher Scientific, Inc.
17.6. Illumina, Inc.
17.7. Danaher Corporation
17.8. Fujifilm Holdings Corporation
17.9. F. Hoffmann-La Roche AG
17.10. Bayer AG
17.11. Bracco Group
17.12. Brainlab SE
17.13. NeoGenomics Laboratories, Inc.
17.14. QIAGEN N.V.
17.15. Laboratory Corporation of America Holdings
17.16. Bio-Techne Corporation
17.17. Tempus AI, Inc.
17.18. Medtronic plc
17.19. Hitachi High-Tech Corporation
17.20. Shanghai United Imaging Healthcare Co., Ltd.
17.21. 10x Genomics, Inc.
17.22. Biocartis NV
17.23. Bruker Corporation
17.24. Bruker Corporation
17.25. Caris Life Sciences
17.26. Carl Zeiss Meditec AG
17.27. Elekta AB
17.28. Esaote S.p.A.
17.29. Gencurix, Inc.
17.30. Guerbet Laboratories Limited
17.31. Hamamatsu Photonics K.K.
17.32. Henry Ford Health
17.33. Lantheus Holdings, Inc.
17.34. MDxHealth
17.35. NantOmics, LLC
17.36. NICO Corporation
17.37. Novocure GmbH
17.38. OncoDNA SA
17.39. Oncologica Limited
17.40. Proscia Inc.
17.41. Quanterix Corporation
17.42. Quibim S.L.
17.43. Quibim, S.L.
17.44. Servier Pharmaceuticals
17.45. Shimadzu Corporation
17.46. Stryker Corporation
17.47. Telix Pharmaceuticals Limited
17.48. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CLOSED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CLOSED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CLOSED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL OPEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL OPEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL OPEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CONTRAST AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RADIOTRACERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RADIOTRACERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RADIOTRACERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL EXTRACTION KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL EXTRACTION KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL EXTRACTION KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PROBES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PROBES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PROBES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL STAINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL STAINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL STAINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL FIXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL FIXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL FIXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL IMAGING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL IMAGING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL IMAGING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL PATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL PATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL BENIGN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL BENIGN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL BENIGN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL CHORDOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL CHORDOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL CHORDOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL MENINGIOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL MENINGIOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL MENINGIOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL MALIGNANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL MALIGNANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL MALIGNANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL ASTROCYTOMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL ASTROCYTOMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL ASTROCYTOMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL TISSUE SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL TISSUE SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL BLOOD SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL BLOOD SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL BLOOD SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL GRADE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL GRADE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL GRADE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL GRADE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL GRADE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL GRADE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL GRADE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL GRADE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL GRADE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL GRADE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL GRADE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL GRADE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL INITIAL DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL INITIAL DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL INITIAL DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 212. GLOBAL SURGICAL PLANNING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 213. GLOBAL SURGICAL PLANNING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL SURGICAL PLANNING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL RADIATION PLANNING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 216. GLOBAL RADIATION PLANNING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 217. GLOBAL RADIATION PLANNING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 218. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 221. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 227. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 230. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 231. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL RESPONSE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 234. GLOBAL RESPONSE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 236. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 239. GLOBAL DISEASE TRACKING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 240. GLOBAL DISEASE TRACKING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 241. GLOBAL DISEASE TRACKING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 242. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 244. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 245. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 246. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 247. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 249. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 250. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 252. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 254. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 255. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 256. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 257. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 258. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 259. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 260. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS, 2017-2032 (USD MILLION)
TABLE 261. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 262. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 263. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2017-2032 (USD MILLION)
TABLE 264. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 265. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2017-2032 (USD MILLION)
TABLE 266. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 267. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 268. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2017-2032 (USD MILLION)
TABLE 269. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2017-2032 (USD MILLION)
TABLE 270. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 271. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 272. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 273. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 274. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 275. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2017-2032 (USD MILLION)
TABLE 276. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 277. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2017-2032 (USD MILLION)
TABLE 279. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 280. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2017-2032 (USD MILLION)
TABLE 281. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 282. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 284. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 285. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 286. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 287. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS, 2017-2032 (USD MILLION)
TABLE 288. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 289. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 290. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2017-2032 (USD MILLION)
TABLE 291. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 292. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2017-2032 (USD MILLION)
TABLE 293. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 294. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 295. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2017-2032 (USD MILLION)
TABLE 296. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2017-2032 (USD MILLION)
TABLE 297. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 298. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 299. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 300. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 301. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 302. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2017-2032 (USD MILLION)
TABLE 303. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 304. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2017-2032 (USD MILLION)
TABLE 305. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2017-2032 (USD MILLION)
TABLE 306. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 307. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2017-2032 (USD MILLION)
TABLE 308. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 309. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 311. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 312. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 313. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 314. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS, 2017-2032 (USD MILLION)
TABLE 315. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 316. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 317. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2017-2032 (USD MILLION)
TABLE 318. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 319. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2017-2032 (USD MILLION)
TABLE 320. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 321. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 322. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2017-2032 (USD MILLION)
TABLE 323. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2017-2032 (USD MILLION)
TABLE 324. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 325. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 326. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 327. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 328. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 329. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2017-2032 (USD MILLION)
TABLE 330. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2017-2032 (USD MILLION)
TABLE 331. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2017-2032 (USD MILLION)
TABLE 332. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2017-2032 (USD MILLION)
TABLE 333. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 334. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2017-2032 (USD MILLION)
TABLE 335. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 336. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 337. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 338. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 339. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 340. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 341. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS, 2017-2032 (USD MILLION)
TABLE 342. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 343. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 344. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2017-2032 (USD MILLION)
TABLE 345. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 346. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2017-2032 (USD MILLION)
TABLE 347. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 348. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 349. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2017-2032 (USD MILLION)
TABLE 350. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2017-2032 (USD MILLION)
TABLE 351. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2017-2032 (USD MILLION)
TABLE 352. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2017-2032 (USD MILLION)
TABLE 353. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2017-2032 (USD MILLION)
TABLE 354. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2017-2032 (USD MILLION)
TABLE 355. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY S

Companies Mentioned

  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Fujifilm Holdings Corporation
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Bracco Group
  • Brainlab SE
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Laboratory Corporation of America Holdings
  • Bio-Techne Corporation
  • Tempus AI, Inc.
  • Medtronic plc
  • Hitachi High-Tech Corporation
  • Shanghai United Imaging Healthcare Co., Ltd.
  • 10x Genomics, Inc.
  • Biocartis NV
  • Bruker Corporation
  • Bruker Corporation
  • Caris Life Sciences
  • Carl Zeiss Meditec AG
  • Elekta AB
  • Esaote S.p.A.
  • Gencurix, Inc.
  • Guerbet Laboratories Limited
  • Hamamatsu Photonics K.K.
  • Henry Ford Health
  • Lantheus Holdings, Inc.
  • MDxHealth
  • NantOmics, LLC
  • NICO Corporation
  • Novocure GmbH
  • OncoDNA SA
  • Oncologica Limited
  • Proscia Inc.
  • Quanterix Corporation
  • Quibim S.L.
  • Quibim, S.L.
  • Servier Pharmaceuticals
  • Shimadzu Corporation
  • Stryker Corporation
  • Telix Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.19 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.03 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned48

Related Topics

Related Reports

Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Head & Neck Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Head & Neck Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Brain Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents & Consumables, Software & AI Solutions), Technique (Imaging, Molecular Diagnostics), Cancer Type, End Use, and Region with Growth Forecasts, 2025-2033 - Product Image

Brain Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Reagents & Consumables, Software & AI Solutions), Technique (Imaging, Molecular Diagnostics), Cancer Type, End Use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 130 Pages
  • Global
From
Brain Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Brain Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From

About the Brain Cancer Diagnostics Market

In the realm of medical diagnostics, the Brain Cancer Diagnostics market is a specialized segment focused on the identification and characterization of brain tumors. Diagnostics for brain cancer are critical for formulating effective treatment plans, as the nature and progression of brain tumors can vary greatly. The market includes various diagnostic modalities such as imaging techniques, biopsy procedures, and molecular and genetic tests. Imaging tests such as MRI and CT scans are often the first step in diagnosing brain cancer, providing detailed images of the brain to detect abnormalities. Biopsies, wherein tissue samples are extracted from the suspected cancerous region, provide definitive diagnosis. Advanced methods to analyze tissue samples include histopathological examination, immunohistochemistry, and molecular testing, which can give insight into specific genetic mutations and markers that may influence treatment strategies. As medical technology advances, the introduction of new diagnostic tools and methods continues to evolve the field. With the integration of artificial intelligence and machine learning, there is a growing potential for improved diagnosis accuracy and personalized treatment approaches. Some notable companies operating in the Brain Cancer Diagnostics market include GE Healthcare, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation, and Agilent Technologies. These organizations are involved in the production of imaging equipment, development of molecular diagnostics, and provision of services essential for the accurate diagnosis and management of brain cancers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.